Published in J Clin Virol on March 01, 2005
Vaginal self-swab specimen collection in a home-based survey of older women: methods and applications. J Gerontol B Psychol Sci Soc Sci (2009) 3.27
Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis (2007) 2.93
Prophylactic human papillomavirus vaccines. J Clin Invest (2006) 2.36
Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma. J Natl Cancer Inst (2009) 2.22
Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J Virol (2007) 2.05
Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the roche linear array HPV genotyping test. J Clin Microbiol (2006) 2.05
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin (2011) 1.73
Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res (2008) 1.73
Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol (2009) 1.70
Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. Int J Cancer (2009) 1.65
Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res (2010) 1.50
Molecular mechanisms of human papillomavirus-induced carcinogenesis. Public Health Genomics (2009) 1.45
The possible involvement of virus in breast cancer. J Cancer Res Clin Oncol (2008) 1.42
The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. PLoS One (2016) 1.40
An armamentarium of wart treatments. Clin Med Res (2006) 1.23
Sexually transmitted diseases in the USA: temporal trends. Sex Transm Infect (2007) 1.21
Molecular mapping of high-grade cervical intraepithelial neoplasia shows etiological dominance of HPV16. Int J Cancer (2012) 1.21
Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis (2008) 1.20
Koilocytosis: a cooperative interaction between the human papillomavirus E5 and E6 oncoproteins. Am J Pathol (2008) 1.19
Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites. Head Neck (2010) 1.16
Proteasomal degradation of the papillomavirus E2 protein is inhibited by overexpression of bromodomain-containing protein 4. J Virol (2009) 1.13
Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J Clin Pathol (2006) 1.11
A genome-wide association study identifies two new cervical cancer susceptibility loci at 4q12 and 17q12. Nat Genet (2013) 1.09
Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol (2013) 1.09
Incidence of anogenital warts in Germany: a population-based cohort study. BMC Infect Dis (2010) 1.08
Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS One (2008) 1.04
Prevalence of human papillomavirus in archival samples obtained from patients with cervical pre-malignant and malignant lesions from Northeast Brazil. BMC Res Notes (2010) 1.03
Towards the eradication of HPV infection through universal specific vaccination. BMC Public Health (2013) 1.01
Acquisition of new infection and clearance of type-specific human papillomavirus infections in female students in Busan, South Korea: a follow-up study. BMC Infect Dis (2008) 1.01
Distribution of HPV genotypes in cervical intraepithelial lesions and cervical cancer in Tanzanian women. Infect Agent Cancer (2011) 1.00
Cervicovaginal self-sampling is a reliable method for determination of prevalence of human papillomavirus genotypes in women aged 20 to 30 years. J Clin Microbiol (2011) 1.00
Evidence for vertical transmission of HPV from mothers to infants. Infect Dis Obstet Gynecol (2010) 1.00
Development and evaluation of a liquid bead microarray assay for genotyping genital human papillomaviruses. J Clin Microbiol (2009) 1.00
Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China. BMC Infect Dis (2015) 1.00
Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination. Am J Public Health (2013) 0.99
High-risk and multiple human papillomavirus (HPV) infections in cancer-free Jamaican women. Infect Agent Cancer (2009) 0.97
Association of genital human papillomavirus infection with HIV acquisition: a systematic review and meta-analysis. Sex Transm Infect (2013) 0.97
Does HPV-status 6-12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence? Eur J Cancer (2007) 0.95
Human papillomavirus is associated with breast cancer in the north part of Iran. ScientificWorldJournal (2012) 0.93
Knowledge of and attitude toward human papillomavirus infection and vaccines among female nurses at a tertiary hospital in Nigeria. Int J Womens Health (2011) 0.93
Chromosomal biomarkers for detection of human papillomavirus associated genomic instability in epithelial cells of cervical cytology specimens. J Mol Diagn (2007) 0.92
Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years. J Korean Med Sci (2010) 0.91
Quality of life valuations of HPV-associated cancer health states by the general population. Sex Transm Infect (2012) 0.91
Distribution patterns of infection with multiple types of human papillomaviruses and their association with risk factors. PLoS One (2011) 0.91
The invisible enemy - how human papillomaviruses avoid recognition and clearance by the host immune system. Open Virol J (2012) 0.91
Multifactorial etiology of cervical cancer: a hypothesis. MedGenMed (2005) 0.90
Human papillomaviruses as therapeutic targets in human cancer. J Clin Oncol (2011) 0.90
Karyopherin beta3: a new cellular target for the HPV-16 E5 oncoprotein. Biochem Biophys Res Commun (2008) 0.90
Human papillomavirus infection in women attended at a cervical cancer screening service in Natal, Brazil. Braz J Microbiol (2008) 0.89
Human papillomavirus: the usefulness of risk factors in determining who should get vaccinated. Rev Obstet Gynecol (2008) 0.89
Human papillomavirus prevalence and type-distribution among women in Zhejiang Province, Southeast China: a cross-sectional study. BMC Infect Dis (2014) 0.87
Anal, penile, and oral high-risk HPV infections and HPV seropositivity in HIV-positive and HIV-negative men who have sex with men. PLoS One (2014) 0.87
Age-specific prevalence of human papilloma virus infection among Nigerian women. BMC Public Health (2014) 0.87
HPV vaccination coverage among women aged 18-20 years in Germany three years after recommendation of HPV vaccination for adolescent girls: results from a cross-sectional survey. Hum Vaccin Immunother (2013) 0.87
HPV infection in esophageal squamous cell carcinoma and its relationship to the prognosis of patients in northern China. ScientificWorldJournal (2014) 0.87
Determinants of newly detected human papillomavirus infection in HIV-infected and HIV-uninfected injection drug using women. Sex Transm Dis (2009) 0.87
Genital human papillomavirus infection among women in Bangladesh: findings from a population-based survey. PLoS One (2014) 0.86
Prevalence and molecular epidemiology of human papillomavirus infection in italian women with cervical cytological abnormalities. J Public Health Res (2014) 0.86
A cross-sectional study to estimate high-risk human papillomavirus prevalence and type distribution in Italian women aged 18-26 years. BMC Infect Dis (2013) 0.85
Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors. Vaccine (2009) 0.85
HPV Infection in Cervical and Other Cancers in Saudi Arabia: Implication for Prevention and Vaccination. Front Oncol (2014) 0.85
Identification and characterization of small molecule human papillomavirus E6 inhibitors. ACS Chem Biol (2014) 0.84
Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis. J Infect Dis (2015) 0.84
Promoter methylation of p16(INK4A), hMLH1, and MGMT in liquid-based cervical cytology samples compared with clinicopathological findings and HPV presence. Infect Dis Obstet Gynecol (2011) 0.84
Human papillomavirus 45 genetic variation and cervical cancer risk worldwide. J Virol (2014) 0.83
Factors associated with genital human papillomavirus infection among adult females in the United States, NHANES 2007-2010. BMC Res Notes (2014) 0.83
When do sexual partnerships need to be accounted for in transmission models of human papillomavirus? Int J Environ Res Public Health (2010) 0.83
Predictors of human papillomavirus infection in women undergoing routine cervical cancer screening in Spain: the CLEOPATRE study. BMC Infect Dis (2012) 0.83
Biphenylsulfonacetic acid inhibitors of the human papillomavirus type 6 E1 helicase inhibit ATP hydrolysis by an allosteric mechanism involving tyrosine 486. Antimicrob Agents Chemother (2005) 0.82
Increasing girls' knowledge about human papillomavirus vaccination with a pre-test and a national leaflet: a quasi-experimental study. BMC Public Health (2013) 0.81
Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health Econ Rev (2012) 0.81
Equity in human papilloma virus vaccination uptake?: sexual behaviour, knowledge and demographics in a cross-sectional study in (un)vaccinated girls in the Netherlands. BMC Public Health (2014) 0.81
Translational potential into health care of basic genomic and genetic findings for human immunodeficiency virus, Chlamydia trachomatis, and human papilloma virus. Biomed Res Int (2013) 0.81
Inhibition of human papillomavirus DNA replication by an E1-derived p80/UAF1-binding peptide. J Virol (2012) 0.80
Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study. Wien Klin Wochenschr (2013) 0.80
Lifestyle and reproductive risk factors associated with anal cancer in women aged over 50 years. Br J Cancer (2015) 0.80
Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome. PLoS One (2015) 0.80
HPV type-related chromosomal profiles in high-grade cervical intraepithelial neoplasia. BMC Cancer (2012) 0.79
Local immunosuppression induced by high viral load of human papillomavirus: characterization of cellular phenotypes producing interleukin-10 in cervical neoplastic lesions. Immunology (2015) 0.79
Possible DNA viral factors of human breast cancer. Cancers (Basel) (2010) 0.79
A large cross-sectional survey investigating the knowledge of cervical cancer risk aetiology and the predictors of the adherence to cervical cancer screening related to mass media campaign. Biomed Res Int (2014) 0.79
Tumour suppressor gene methylation and cervical cell folate concentration are determinants of high-risk human papillomavirus persistence: a nested case control study. BMC Cancer (2014) 0.78
Correlates of human papillomavirus vaccination among female university students. Women Health (2014) 0.77
A clinical and genetic analysis of multiple primary cancer referrals to genetics services. Eur J Hum Genet (2014) 0.77
Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines. Eur J Pediatr (2009) 0.77
[Precancerous lesions of the uterine cervix: morphology and molecular pathology]. Pathologe (2011) 0.77
Knowledge about human papillomavirus and the human papillomavirus vaccine in Belgian students. Cent European J Urol (2014) 0.77
Specificity of L1 peptides versus virus-like particles for detection of human papillomavirus-positive cervical lesions in females attending Engativa Hospital, Bogota, Colombia. J Clin Microbiol (2008) 0.77
Genetic variants in RAN, DICER and HIWI of microRNA biogenesis genes and risk of cervical carcinoma in a Chinese population. Chin J Cancer Res (2013) 0.77
HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities. BMC Infect Dis (2017) 0.77
[Human papillomavirus infection. Pathology and molecular pathology]. Pathologe (2008) 0.76
HPV Infection-Associated Cancers: Next-Generation Technology for Diagnosis and Treatment. Cancer Immunol Res (2014) 0.76
HLA-DRB1 Class II antigen level alleles are associated with persistent HPV infection in Mexican women; a pilot study. Infect Agent Cancer (2013) 0.76
Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world? Ann Med Health Sci Res (2013) 0.76
The combined influence of oral contraceptives and human papillomavirus virus on cutaneous squamous cell carcinoma. Clin Med Insights Oncol (2011) 0.76
Distribution of human papillomavirus (HPV) genotypes detected by routine pap smear in Uyghur-Muslim women from Karasay Township Hotan (Xinjiang, China). J Med Virol (2015) 0.76
Expanding the scope of nursing research in low resource and middle resource countries, regions, and states focused on cervical cancer prevention, early detection, and control. J Natl Black Nurses Assoc (2009) 0.75
Estimation of cancer burden in Brezice municipality, a community neighboring Krsko nuclear power plant in Slovenia. Croat Med J (2008) 0.75
Prevalence of human papillomavirus type 58 in women with or without cervical lesions in northeast Brazil. Ann Med Health Sci Res (2013) 0.75
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol (2003) 7.35
Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med (2006) 5.69
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis (2007) 3.48
Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis (2008) 3.19
Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis (2004) 3.18
Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med (2008) 2.98
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst (2006) 2.67
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck (2009) 2.59
Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis (2005) 2.51
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Genital human papillomavirus infection in men. Lancet Infect Dis (2006) 2.39
Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sex Transm Dis (2006) 2.21
Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J Infect Dis (2002) 2.09
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis (2002) 1.99
Clinical findings among young women with genital human papillomavirus infection. Am J Obstet Gynecol (2003) 1.91
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect (2011) 1.78
Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev (2011) 1.74
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3. J Natl Cancer Inst (2009) 1.65
Obtaining sensitive data through the Web: an example of design and methods. Epidemiology (2002) 1.61
Rates and determinants of oral human papillomavirus infection in young men. Sex Transm Dis (2012) 1.48
Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol Biomarkers Prev (2007) 1.43
High rates of incident and prevalent anal human papillomavirus infection among young men who have sex with men. J Infect Dis (2013) 1.38
Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev (2010) 1.34
p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol (2003) 1.27
Concordance of self-collected and clinician-collected swab samples for detecting human papillomavirus DNA in women 18 to 32 years of age. Sex Transm Dis (2007) 1.27
Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine (2009) 1.24
Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev (2010) 1.21
Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol (2006) 1.20
Comparison of incident cervical and vulvar/vaginal human papillomavirus infections in newly sexually active young women. J Infect Dis (2009) 1.18
Relationship between cigarette smoking and human papilloma virus types 16 and 18 DNA load. Cancer Epidemiol Biomarkers Prev (2009) 1.18
Detection of genital HPV types in fingertip samples from newly sexually active female university students. Cancer Epidemiol Biomarkers Prev (2010) 1.18
Men's perceptions and knowledge of human papillomavirus (HPV) infection and cervical cancer. J Am Coll Health (2005) 1.12
Human Papillomavirus (HPV) type 16 and type 18 DNA Loads at Baseline and Persistence of Type-Specific Infection during a 2-year follow-up. J Infect Dis (2009) 1.09
Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis (2008) 1.09
Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia. Am J Epidemiol (2004) 1.08
Determinants of cervical cancer rates in developing countries. Int J Cancer (2002) 1.08
Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study. J Infect Dis (2011) 1.08
Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. Mayo Clin Proc (2005) 1.08
Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development. J Med Virol (2009) 1.06
Antibody responses in oral fluid after administration of prophylactic human papillomavirus vaccines. J Infect Dis (2009) 1.05
Serum antibody response following genital {alpha}9 human papillomavirus infection in young men. J Infect Dis (2011) 1.05
Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. J Clin Virol (2011) 1.01
Effect of cervical cytologic status on the association between human papillomavirus type 16 DNA load and the risk of cervical intraepithelial neoplasia grade 3. J Infect Dis (2008) 1.01
Development and evaluation of a liquid bead microarray assay for genotyping genital human papillomaviruses. J Clin Microbiol (2009) 1.00
Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples. J Low Genit Tract Dis (2010) 0.99
Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine (2004) 0.99
Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers. J Virol (2005) 0.98
Prevalence and risk factors for oncogenic human papillomavirus infections in high-risk mid-adult women. Sex Transm Dis (2012) 0.96
Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomarkers Prev (2002) 0.96
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. Int J Cancer (2011) 0.95
Using risk factors to predict human papillomavirus infection: implications for targeted vaccination strategies in young adult women. Vaccine (2007) 0.95
Evaluation of dry and wet transport of at-home self-collected vaginal swabs for human papillomavirus testing. J Med Microbiol (2012) 0.95
Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection. Am J Obstet Gynecol (2009) 0.94
Smokers at higher risk for undetected antibody for oncogenic human papillomavirus type 16 infection. Cancer Epidemiol Biomarkers Prev (2006) 0.94
Inverse association between methylation of human papillomavirus type 16 DNA and risk of cervical intraepithelial neoplasia grades 2 or 3. PLoS One (2011) 0.94
Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine (2004) 0.94
Development of genital warts after incident detection of human papillomavirus infection in young men. J Infect Dis (2010) 0.93
Association of human papillomavirus type 31 variants with risk of cervical intraepithelial neoplasia grades 2-3. Int J Cancer (2012) 0.92
Evaluation of transported dry and wet cervical exfoliated samples for detection of human papillomavirus infection. J Clin Microbiol (2010) 0.91
Persistence of newly detected human papillomavirus type 31 infection, stratified by variant lineage. Int J Cancer (2012) 0.90
Age of diagnosis of squamous cell cervical carcinoma and early sexual experience. Cancer Epidemiol Biomarkers Prev (2009) 0.90
Viral load and short-term natural history of type-specific oncogenic human papillomavirus infections in a high-risk cohort of midadult women. Int J Cancer (2013) 0.89
Characterization of IgA response among women with incident HPV 16 infection. Virology (2003) 0.89
Circumcision and acquisition of human papillomavirus infection in young men. Sex Transm Dis (2011) 0.87
Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines. Clin Vaccine Immunol (2007) 0.86
Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. Int J Cancer (2007) 0.86
Comparison of oral fluid and serum ELISAs in the determination of IgG response to natural human papillomavirus infection in university women. J Clin Virol (2005) 0.86
Human papillomavirus type 16 variants in paired enrollment and follow-up cervical samples: implications for a proper understanding of type-specific persistent infections. J Infect Dis (2010) 0.85
Liquid-based Papanicolaou smears without a transformation zone component: should clinicians worry? Obstet Gynecol (2002) 0.84
Risk of cervical intraepithelial neoplasia grade 2 or 3 after loop electrosurgical excision procedure associated with human papillomavirus type 16 variants. J Infect Dis (2007) 0.84
Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States. Am J Obstet Gynecol (2008) 0.83
Prevalence of high-risk HPV types and abnormal cervical cytology in American Indian/Alaska Native women, 2003-2005. Public Health Rep (2011) 0.82
Disclosure of genital human papillomavirus infection to female sex partners by young men. Sex Transm Dis (2012) 0.81
Human papillomavirus through the ages. J Infect Dis (2005) 0.81
Delivering reassurance to parents: perinatal human papillomavirus transmission is rare. Sex Transm Dis (2004) 0.81
Influence of loop electrosurgical excision procedure on subsequent acquisition of new human papillomavirus infections. J Infect Dis (2009) 0.81
Evaluation of an ELISA for p16INK4a as a screening test for cervical cancer. Cancer Epidemiol Biomarkers Prev (2009) 0.81
Potential impact of human papillomavirus vaccines on public STD clinic workloads and on opportunities to diagnose and treat other sexually transmitted diseases. Sex Transm Dis (2007) 0.81
The association of current hormonal contraceptive use with type-specific HPV detection. Sex Transm Infect (2011) 0.79
National burden of genital warts: a first step in defining the problem. Sex Transm Dis (2008) 0.79
Sequence variation of human papillomavirus type 16 and measurement of viral integration by quantitative PCR. J Clin Microbiol (2008) 0.78
Should liquid-based cytology be repeated at the time of colposcopy? J Low Genit Tract Dis (2005) 0.77
Re: Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst (2004) 0.77
Determinants of High-Risk Human Papillomavirus Seroprevalence and DNA Prevalence in Mid-Adult Women. Sex Transm Dis (2016) 0.76
Difficulties in estimating the male-to-female sexual transmissibility of human papillomavirus infection. Sex Transm Dis (2009) 0.76
Incidence of oral human papillomavirus infection. Lancet (2013) 0.75
Epidemiology of Human Papillomavirus Detected in the Oral Cavity and Fingernails of Mid-Adult Women. Sex Transm Dis (2015) 0.75
Would young women attending sexually transmitted disease clinics benefit from human papillomavirus vaccination? An assessment of human papillomavirus DNA and seropositivity from human papillomavirus sentinel surveillance, 2003-2005. Sex Transm Dis (2014) 0.75